## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

|                                                      | by the Registrant ⊔<br>by a Party other than the Registrant ☑                                                                                                                                                                                                              |
|------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Check                                                | the appropriate box:                                                                                                                                                                                                                                                       |
| <ul> <li>□ Co</li> <li>□ De</li> <li>☑ De</li> </ul> | climinary Proxy Statement  Infidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Infinitive Proxy Statement  Infinitive Additional Materials  Identify Material Pursuant to §240.14a-12                                                          |
|                                                      | CNS RESPONSE, INC.                                                                                                                                                                                                                                                         |
|                                                      | (Name of Registrant as Specified In Its Charter)                                                                                                                                                                                                                           |
|                                                      | Leonard J. Brandt                                                                                                                                                                                                                                                          |
|                                                      | (Name of Person(s) Filing Proxy Statement, if other than the Registrant)                                                                                                                                                                                                   |
| •                                                    | ent of Filing Fee (Check the appropriate box):                                                                                                                                                                                                                             |
|                                                      | fee required. c computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.                                                                                                                                                                                       |
|                                                      | Title of each class of securities to which transaction applies:                                                                                                                                                                                                            |
|                                                      | ···                                                                                                                                                                                                                                                                        |
| (2)                                                  | Aggregate number of securities to which transaction applies:                                                                                                                                                                                                               |
| (3)                                                  | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):                                                                          |
| (4)                                                  | Proposed maximum aggregate value of transaction:                                                                                                                                                                                                                           |
| (5)                                                  | Total fee paid:                                                                                                                                                                                                                                                            |
| □ Fee                                                | e paid previously with preliminary materials.                                                                                                                                                                                                                              |
| off                                                  | eck box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the setting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and date of its filing. |
| (1)                                                  | Amount Previously Paid:                                                                                                                                                                                                                                                    |
| (2)                                                  | Form, Schedule or Registration Statement No.:                                                                                                                                                                                                                              |
| (3)                                                  | Filing Party:                                                                                                                                                                                                                                                              |
| (4)                                                  | Date Filed:                                                                                                                                                                                                                                                                |
|                                                      |                                                                                                                                                                                                                                                                            |

## Len Brandt

lenjbrandt@gmail.com 31878 Del Obispo St., Suite 118-131 San Juan Capistrano, CA 92675 Fax: (949) 743-2785

September 3, 2009

RE: Len Brandt's comments on the e-mail of Larry Baill to stockholders

Dear CNS Response Shareholders,

Sometimes friends can be a little predisposed by their friendship. I think such is the case with a letter mailed to some shareholders last night by Larry Baill. In fact, that letter shows the kind of fervor for his position that can inspire the most successful legal minds, such as Larry Baill of Yost and Baill.

Although I am complimented by Larry's statements, I cannot accept the praise without commenting. I am not going to be able to offer my view of every statement that was in his e-mail, but here are a few of the necessary corrections.

It was Steve Suffin, MD and W. Hamlin Emory, MD who, through their early faith and constant efforts, envisioned the phenomenal promise of this treatment approach to mental illness – I was not first to see it. And frankly, several other forgotten pioneers are part of this history.

It was Steve Suffin, Hamlin Emory, Brian MacDonald and I who gave birth to the first CNS Response, the California company that became a subsidiary of CNS Response, Inc. in 2007. Frankly, even though Steve or I may get some credit there are others whose efforts outweigh either of our contributions. I believe that invention is 97% sweat as well as inspiration. It took me years to truly understand the challenge of managing treatment-resistant patients to a drug free state and then tracking their entire history of treatment in a usable way. At the beginning, it was absolutely unthinkable to attempt to develop a database of the kind CNS now has. Dr. Suffin conceived the database approach with Dr. Emory, who then set about doing the lion's share of data/patient collection.

When Dr. Suffin took on the full time start-up job with us, it was his family that persevered through the economic challenges and Steve's long hours away from his family. When that reached its limit, it was Dr. Emory who took on the role of Medical Director. He trained the current Chief Medical Officer. It was Brian MacDonald who made the commitment to become the lead engineer, being trained by Dr. Suffin to fill the role, not the one he ever envisioned. The physician demanded an order of magnitude more resolution in the product to make it truly compelling, and Brian developed it. Brian and Dr. Emory went back into the data with the algorithms and came out with it. It worked. In fact, these two people, Brian and Dr. Emory, accomplished something bigger than any of us envisioned, certainly not me.

## Len Brandt

lenjbrandt@gmail.com 31878 Del Obispo St., Suite 118-131 San Juan Capistrano, CA 92675 Fax: (949) 743-2785

Daniel Hoffman, MD, adopted this dream as if it were his own baby. CNS Response may not have survived without him. More than that, trained by Dr. Emory, he saw in his own clinic what he described as the most important development since Freud and started the snowball rolling amongst numerous frustrated physicians. I might have quided physicians to trial, but he quided them to success.

I also have to acknowledge that the dream has been alive because of a few other people. One is Barry Kass. Delivering passion, commitment and credibility, he opened doors at Stanford and Harvard that allowed others to go through. It gave CNS external scientific leadership of the highest caliber. Back in the shop one person throughout it all made CNS reliable. I won't embarrass MM with more than initials. But talk is cheap. Reliability and commitment is hard to come by.

So, though this letter comes at a difficult time in the CNS history, when financial interests are now fighting over its control. I think the company has this opportunity for true greatness because a few people really did dare to matter.

I thank Larry for the compliments where appropriate and the opportunity to set the record straight.

Sincerely,

Leu Brandt